Pluristem Shoots Higher On ‘Buy’ Rating (PSTI, ASTM, BTX, STEM, ATHX, CYTX, GERN)
Pluristem Therapeutic (PSTI), the Israel-based bio-therapeutics firm, is up 13% today after National Securities initiated coverage of the maker of cell therapy products with a “buy” rating. National Securities is bullish on Pluristem’s cell delivery and homing capabilities and sees a significant catalyst in a pending trial with European and U.S. regulators. Volume in Pluristem is almost eight times the daily average usually seen at this point in the trading day.
Overall, the Stem Cell Stocks Index is up 1.5% today. Despite the bullish analyst coverage of Pluristem, the stock is not the top gainer in the Index today. That honor goes to Aastrom Biosciences (ASTM), which is up 15% after an independent report said 2011 “should be a transformative year” for the company. Aastrom Biosciences specializes in cell therapies for chronic cardiovascular diseases.
BioTime (BTX) and StemCells (STEM) are both higher by 2% on no news. Athersys Inc (ATHX) and Cytori Therapeutics, Inc. (CYTX) are the worst performers in the Index today, each with losses of 2% or more. Geron (GERN), the largest Index constituent by market value, is lower by 1%.
Investors can track the Stem Cell Stocks Index for performance trends and a suite of other metrics at tickerspy.com.
|Home | Find | Research | Track | Register | My Account | Logout||Web site design by LightMix|
|© 2011 Indie research Corp. All rights reserved.|